Showing results (61-70 of 290) with videos related to
Sort By:
Pageof 29
Case Reports in Oncology|July 3, 2014
Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to VemurafenibSiraj M Ali, Je He, Wade Carson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinibMelissa L Johnson, Greg J Riely, Naiyer A Rizvi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to PazopanibVinod Ravi, Eric M Sanford, Wei-Lien Wang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibGregory J Riely, William Pao, Duykhanh Pham, et al.Lung Cancer (Amsterdam, Netherlands)|March 5, 2015
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinibSai-Hong Ignatius Ou, Joel Greenbowe, Ziad U Khan, et al.The Oncologist|January 27, 2019
Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior TestingLise Boussemart, Annie Nelson, Michael Wong, et al.Clinical Lung Cancer|April 26, 2015
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-ReviewSamuel J Klempner, Sai-Hong Ignatius Ou, Daniel B Costa, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.Plos Medicine|February 8, 2005
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibWilliam Pao, Theresa Y Wang, Gregory J Riely, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersHelena A Yu, Maria E Arcila, Natasha Rekhtman, et al.Pageof 29